Top Companies in the Global Mastopexy Market in 2025

The global mastopexy market was valued at USD 1.87 billion in 2024, driven by the increasing demand for aesthetic procedures and rising acceptance of cosmetic surgery across the globe. The market is anticipated to grow at a CAGR of 5.69% during the forecast period of 2025-2034, with the values likely to reach USD 3.25 billion by 2034.

Mastopexy, also known as a breast lift, is a surgical procedure designed to raise and reshape sagging breasts. This procedure involves the removal of excess skin and tightening of the surrounding tissue to improve the breast's contour and restore a more youthful appearance. Mastopexy can be performed alone or in conjunction with breast augmentation, depending on the patient's needs and desired outcomes. This increasingly popular procedure is driven by various factors, including ageing, pregnancy, weight loss, and genetics, all contributing to changes in breast shape and firmness.

The global mastopexy market has been experiencing significant growth, driven by the increasing demand for aesthetic enhancement procedures and the growing awareness about breast surgeries. As more women seek solutions for breast sagging, the demand for breast lifts continues to rise. Furthermore, advancements in surgical techniques and the adoption of new technologies are contributing to the market's expansion.

The introduction of dissolvable mesh in breast lifting procedures initiated a significant trend resulting in increased adoption worldwide. For instance, in February 2020, a pioneering surgeon at Fox Chase Cancer Center in the US published positive results from using a new resorbable mesh in breast reconstruction procedures. The new mesh, Phasix, was used to reinforce the abdominal wall in patients undergoing breast reconstruction, minimizing the risk of hernias and bulges, a common issue with traditional sutures. The resorbable mesh offers the advantage of reducing long-term complications, such as infection, which are associated with permanent mesh materials like polypropylene. This innovation could significantly enhance the quality and safety of mastopexy surgeries, offering better outcomes and reducing the need for revision procedures.

Further, ongoing research into improving existing procedures is another significant trend in the market. Surgeons are continuously exploring more efficient methods to enhance the aesthetic outcomes and safety of mastopexy surgeries. Studies are investigating the use of autologous tissue for breast lifts, as well as the development of less invasive techniques to reduce recovery times and complications. In addition, surgeons are focusing on creating more personalised techniques that cater to different body types, ensuring that each patient receives the most suitable treatment for their needs.

The mastopexy market is also experiencing a surge in the development of new surgical devices and technologies aimed at improving precision during procedures. Innovations like 3D imaging and computer-assisted surgical systems are helping surgeons achieve better aesthetic results while ensuring higher patient safety.

Major Companies Shaping the Mastopexy Market in 2025

1.    AbbVie Inc.

AbbVie Inc., headquartered in North Chicago, Illinois, is a global biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. Through its acquisition of Allergan in 2020, AbbVie expanded into the aesthetics market, offering products like Natrelle breast implants, widely used in mastopexy procedures. In November 2023, AbbVie launched its “For Every BODY” campaign under the Natrelle brand, highlighting the wide customization options available for various body types. The initiative aimed to educate women on implant choices during consultations, reinforcing AbbVie’s commitment to inclusivity and innovation in aesthetic solutions. The company maintains a strong global presence across more than 170 countries.

2.    Sientra

Founded in 2003 and based in Santa Barbara, California, Sientra specialized in breast implants and body contouring solutions. In February 2024, the company filed for Chapter 11 bankruptcy and subsequently sold its breast implant business to Tiger Aesthetics Medical, LLC in April 2024. Tiger Aesthetics has assumed all warranties and customer contracts. Additionally, Sientra's Biocorneum scar treatment line was acquired by Nuance Intermediary, LLC, marking a significant shift in the company's operations.

3.    POLYTECH Health & Aesthetics GmbH

Established in 1986 in Dieburg, Germany, POLYTECH Health & Aesthetics GmbH is a manufacturer of soft tissue implants. The company offers an extensive range of over 2,000 breast and body-contouring implant options, including the innovative B-Lite® lightweight implants, which are up to 30% lighter than traditional implants. POLYTECH's commitment to quality and patient safety has solidified its reputation in over 80 countries worldwide.

4. Johnson & Johnson Services Inc.

With its headquarters in New Brunswick, New Jersey, Johnson & Johnson Services Inc. has been a leader in healthcare since 1886. The company offers a wide range of consumer healthcare products, including brands like Neutrogena, Aveeno, and Listerine. In the mastopexy market, its subsidiary, Mentor Worldwide LLC, provides FDA-approved breast implants, such as the MemoryGel line, catering to both reconstructive and aesthetic needs.

5. Cynosure

Cynosure, based in Westford, Massachusetts, is a pioneer in energy-based aesthetic and medical treatment systems. The company develops and manufactures a diverse range of applications, including laser and radiofrequency technologies for skin revitalization, scar treatment, and body contouring. Cynosure's innovative solutions are utilized globally by practitioners to enhance patient outcomes in various aesthetic procedures, including mastopexy.

6. Mentor Worldwide

Founded in 1969 and headquartered in Santa Barbara, California, Mentor Worldwide LLC is a subsidiary of Johnson & Johnson. The company specializes in breast aesthetics, offering products like the MemoryGel and Contour Profile Gel breast implants, which are widely used in mastopexy surgeries. Mentor's commitment to quality and innovation has made it a trusted name among plastic surgeons worldwide.

7. Lumenis

Lumenis, headquartered in Israel, offers energy-based aesthetic solutions that complement mastopexy procedures. Its CO₂ and IPL laser systems support skin resurfacing and scar reduction, enhancing surgical outcomes. By offering minimally invasive technologies, Lumenis helps plastic surgeons improve skin tightening and healing post-mastopexy, making it a valuable player in adjunctive aesthetic treatments.

8. SOLTA Medical

Based in Washington, SOLTA Medical provides non-invasive skin tightening systems like Thermage, which can enhance mastopexy outcomes by improving skin elasticity. Their technologies are often used in combination with surgical procedures to deliver longer-lasting, smoother results. The company’s innovation in radiofrequency-based skin treatments supports post-operative care and patient satisfaction in breast lift surgeries.

9. Syneron Medical

Syneron Medical, now part of Candela, develops energy-based systems such as elōs Plus and CO₂RE, which are widely used for skin tightening and scar treatment post-mastopexy. These technologies help improve the aesthetic finish of breast lifts, reduce recovery time, and enhance skin tone, making them valuable additions to mastopexy procedures.

10. Galderma

Galderma, headquartered in Switzerland, contributes to mastopexy through its range of aesthetic injectables, including Sculptra and Restylane. While not surgical, these products are often used for complementary breast contouring or volume correction post-mastopexy. Galderma’s dermatological expertise supports less invasive enhancements, giving surgeons more options to refine mastopexy outcomes.

11. GC Aesthetics

GC Aesthetics, based in Ireland, specialises in breast implants under brands like Eurosilicone and Nagor, often used alongside mastopexy to restore breast volume and shape. In December 2024, the company launched a major multi-centre clinical study across Europe to evaluate the safety, effectiveness, and patient satisfaction of its PERLE™ smooth opaque round breast implant. By involving NHS and private surgeons, GC Aesthetics reinforces its commitment to evidence-based, high-quality outcomes in both aesthetic and reconstructive breast procedures, supporting customised care for mastopexy patients.